Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia.

被引：0
|
作者：
Chanan-Khan, Asher
Liu, Tom
Yang, Keri
Cohen, Aileen
Fahrbach, Kyle
Campbell, Joanna
Tang, Boxiong
机构：
[1] Mayo Clin, Jacksonville, FL USA
[2] BeiGene Inc, San Mateo, CA USA
[3] Evidera, Lexington, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19514
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Commentary on “real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies”
    Ali Beheshti Namdar
    Masoud Keikha
    BMC Pharmacology and Toxicology, 26 (1)
  • [42] Preclinical evaluation of mosunetuzumab for the treatment of relapsed/refractory chronic lymphocytic leukemia
    Barrett, Kathy
    Lu, Kai
    Jin, Hyun Yong
    Millen, Rosie
    Lefebure, Marcus
    Jiang, Yanwen
    CANCER RESEARCH, 2023, 83 (07)
  • [43] MULTIVARIATE NETWORK META-ANALYSIS OF PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL
    Jansen, J. P.
    Trikalinos, T.
    VALUE IN HEALTH, 2013, 16 (07) : A617 - A617
  • [44] Optimizing Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Mato, Anthony
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (5.5): : 581 - 583
  • [45] Genomic aberrations and survival in chronic lymphocytic leukemia.
    Döhner, H
    Stilgenbauer, S
    Benner, A
    Leupolt, E
    Kröber, A
    Bullinger, L
    Döhner, K
    Bentz, M
    Lichter, P
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26): : 1910 - 1916
  • [46] Thalidomide is active alone and in combination with fludarabine in fludarabine-relapsed and refractory chronic lymphocytic leukemia.
    Furman, RR
    Allen, SL
    Leonard, JP
    Coleman, M
    Markis, JM
    Gabrilove, JL
    BLOOD, 2004, 104 (11) : 291B - 291B
  • [47] Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy
    Freise, Kevin J.
    Jones, Aksana K.
    Menon, Rajeev M.
    Verdugo, Maria E.
    Humerickhouse, Rod A.
    Awni, Walid M.
    Salem, Ahmed Hamed
    HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 679 - 684
  • [48] A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia
    Cheng, Mindy M.
    Goulart, Bernardo
    Veenstra, David L.
    Blough, David K.
    Devine, Emily Beth
    CANCER TREATMENT REVIEWS, 2012, 38 (08) : 1004 - 1011
  • [49] Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia
    McCune, SL
    Gockerman, JP
    Moore, JO
    Decastro, CM
    Bass, AJ
    Chao, NJ
    Long, GD
    Vredenburgh, JJ
    Gasparetto, C
    Adams, D
    Payne, N
    Rizzieri, DA
    LEUKEMIA & LYMPHOMA, 2002, 43 (05) : 1007 - 1011
  • [50] Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
    Handunnetti, Sasanka
    Anderson, Mary Ann
    Roberts, Andrew W.
    Davids, Matthew S.
    Ma, Shuo
    Boyer, Michelle
    Arzt, Jennifer
    Al Masud, Abdullah
    Popovic, Relja
    Jacobson, Amanda
    Kim, Su Y.
    Seymour, John F.
    EJHAEM, 2021, 2 (02): : 266 - 271
12345